Abstract
Optimer Pharmaceuticals and Astellas Pharma have teamed up again for the development and commercialisation of fidaxomicin, Optimer’s twice-daily antibiotic for Clostridium difficile infection, this time in Japan. The two companies share a similar arrangement in Europe and certain other countries in the Middle East, Africa and the CIS. Approved by both the US FDA and the EMA, fidaxomicin is sold as Dificid® in the US and will be launched as Dificlir™ in Europe in 2012.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
